Oblique Agreement

      Oblique Therapeutics has entered an agreement with a large pharmaceutical company in the US to apply the AbiProt® technology to generate antibodies to a high-value target. This agreement, if successful, will generate milestones and royalties and includes an option for additional targets.

      Please contact business_development@obliquet.com for more information